carocell bio


Carocell Bio is passionate about developing new treatments for patients with inflammatory diseases. Its leadership team has extensive global experience in drug development and is committed to developing medicines that will improve the patient experience of living with these serious conditions

Meet the team


Dr Mike Davies - Founder, Chief Executive Officer and Chief Medical Officer

Mike is an experienced professional with a significant record as a pharmaceutical researcher and developer. He has worked in the pharmaceutical industry for over 20 years, spending time in large/medium pharma (Pfizer, AstraZeneca, Shire, HealthPoint) and biotech (Serentis, Renovo, Blueberry Therapeutics).

Key achievements:

  • Extensive preclinical and clinical research experience across all phases of drug and device development and marketing
  • Scientific and medical expertise and leadership of global product strategies from concept to registration and throughout the life-cycle of significant drugs and devices
  • Global lead on European and US clinical trials, including design and evaluation of ethical, high-quality clinical trials in multiple therapeutic areas: gastro-intestinal (particularly IBD), dermatology, wound healing, tissue repair, diabetes, cardiovascular, respiratory, rare diseases, renal, rheumatology, oncology and haematology
  • Co-founder and Chief Medical Officer of biotech company focused on nano-formulation of drugs to treat infection, taking their first compound into the clinic and leading pre-IND and IND interactions with the FDA
  • Extensive device experience, including diabetes glucose monitoring and insulin delivery, and biosimilars delivery
  • Developed over 15 patents in the discovery of anti-fungal, anti-inflammatory, wound healing, dermatology and cardiovascular compounds


Patrick Doyle - Chairman

Patrick has over 20 years’ global executive leadership experience in big pharma (Novo Nordisk, Roche) and biotech (Metabolex, Syntaxin, Kareus, KineMed, Synthorx, Stelexis). Throughout his career he has advanced the biopharmaceutical field by working diligently to accomplish ambitious R&D and business goals.

He has catapulted various early and mid-stage healthcare companies to a higher status through fundraising and executing productive licenses and alliances with organizations in countries around the world, especially in Asia and Japan.

Patrick’s areas of expertise and success include start-up and biotech leadership including business development and overall R&D strategic development.

Professor John Mclaughlin, BSc (Hons) MB ChB(Hons) PhD FRCP

John McLaughlin is Professor of Gastroenterology and Nutrition and Head of the Division of Diabetes, Endocrinology and Gastroenterology in the Faculty of Biology, Medicine and Health at the University of Manchester.

Professor Mamta Shah PhD, FRCS

Professor Mamta Shah is a Consultant Children’s Burns and Plastic Surgeon based at the Royal Manchester Children’s Hospital, Wythenshawe hospital and the University of Manchester. She has a special interest in the management of paediatric burn injuries and post-burn scarring. She leads a group of researchers investigating the pathophysiology of burn wound healing and post-burn scarring at the University of Manchester and collaborates with colleagues at other universities


Talk to us

If you would like to speak to us in detail about investing, tax benefits, donating or assisting us in any way at all, please contact us via the details below and we will get back to you as soon as possible.

bridge biotec facebookbridge biotec twitterbridge biotec linkedinbridge-youtube-60x60.png


UK: +44 (0) 20 3097 1979
US: +1 212 863 9902

USA Office

Carocell Bio, Inc.
500 Delaware Avenue
Ste#1, 1960
DE 19899

UK Office

©2018 Carocell Bio Ltd.

The BioHub at Alderley Park
Mereside, Alderley Park
SK10 4TG